Investments
19Portfolio Exits
9About Dafna Capital Management
DAFNA Capital Management, a Los Angeles based SEC registered investment advisor, specializes in managing long/short portfolios of predominantly publicly traded biotechnology and medical device companies. DAFNA Capital Management's principal mission is capital preservation and strong annualized return over longer time periods with minimum risk. Investment returns are generated as a product of recognizing our responsibility to improve human health through the efficient allocation of capital to the most promising preventive, diagnostic, and therapeutic interventions.
Want to inform investors similar to Dafna Capital Management about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Dafna Capital Management News
Jul 29, 2016
Fremont-based biopharmaceuticals developer Ardelyx said Friday that it has received $110M in a private placement, which came from both new and existing investors, including New Enterprise Assocaites (NEA), plus Australia's Future Fund, Quadrille Capital, EcoR1 Capital, RA Capital Management, First Manhattan Co., Rock Springs Capital, Cormorant Asset Management, Perceptive Advisors, Deerfield and DAFNA Capital Management The story you have requested is only available to paid members of the silicontap.com web site. Stories newer than 15 days are restricted to paid members only. Please login in order to access this members-only content, or become a member.
Dafna Capital Management Investments
19 Investments
Dafna Capital Management has made 19 investments. Their latest investment was in KAHR as part of their Series D on June 6, 2021.
Dafna Capital Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/16/2021 | Series D | KAHR | $46.5M | Yes | 15 | |
2/8/2021 | PIPE | Gemini Therapeutics | $95M | Yes | 5 | |
7/15/2016 | PIPE | Ardelyx | $110M | Yes | 4 | |
2/11/2011 | PIPE | |||||
10/14/2008 | PIPE |
Date | 6/16/2021 | 2/8/2021 | 7/15/2016 | 2/11/2011 | 10/14/2008 |
|---|---|---|---|---|---|
Round | Series D | PIPE | PIPE | PIPE | PIPE |
Company | KAHR | Gemini Therapeutics | Ardelyx | ||
Amount | $46.5M | $95M | $110M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 15 | 5 | 4 |
Dafna Capital Management Portfolio Exits
9 Portfolio Exits
Dafna Capital Management has 9 portfolio exits. Their latest portfolio exit was Gemini Therapeutics on August 10, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/10/2022 | Acq - Pending | 2 | |||
Date | 8/10/2022 | ||||
|---|---|---|---|---|---|
Exit | Acq - Pending | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 |
Dafna Capital Management Team
1 Team Member
Dafna Capital Management has 1 team member, including current Controller, Xun Lin.
Name | Work History | Title | Status |
|---|---|---|---|
Xun Lin | Controller | Current |
Name | Xun Lin |
|---|---|
Work History | |
Title | Controller |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
